Seven Springs Wealth Group LLC bought a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 4,005 shares of the company's stock, valued at approximately $339,000.
Other large investors have also recently modified their holdings of the company. Assetmark Inc. bought a new position in shares of Axsome Therapeutics during the 4th quarter worth $52,000. R Squared Ltd bought a new position in shares of Axsome Therapeutics during the fourth quarter valued at approximately $64,000. KBC Group NV increased its holdings in Axsome Therapeutics by 40.5% during the fourth quarter. KBC Group NV now owns 1,336 shares of the company's stock valued at $113,000 after buying an additional 385 shares during the period. Xponance Inc. raised its stake in Axsome Therapeutics by 11.6% in the fourth quarter. Xponance Inc. now owns 2,659 shares of the company's stock worth $225,000 after buying an additional 277 shares in the last quarter. Finally, Intrust Bank NA lifted its holdings in Axsome Therapeutics by 6.9% during the fourth quarter. Intrust Bank NA now owns 2,823 shares of the company's stock worth $239,000 after buying an additional 183 shares during the period. Hedge funds and other institutional investors own 81.49% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on AXSM shares. HC Wainwright restated a "buy" rating and set a $200.00 price objective on shares of Axsome Therapeutics in a research note on Thursday, April 3rd. Robert W. Baird lifted their price objective on shares of Axsome Therapeutics from $132.00 to $160.00 and gave the stock an "outperform" rating in a research report on Monday, March 3rd. Truist Financial increased their target price on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a research report on Wednesday, February 19th. Royal Bank of Canada lifted their price target on shares of Axsome Therapeutics from $143.00 to $192.00 and gave the stock an "outperform" rating in a report on Wednesday, February 19th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Axsome Therapeutics in a research note on Tuesday, February 11th. They issued a "buy" rating and a $176.00 target price for the company. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $169.80.
View Our Latest Research Report on Axsome Therapeutics
Axsome Therapeutics Trading Up 0.8 %
Axsome Therapeutics stock traded up $0.86 during midday trading on Friday, hitting $106.27. 438,984 shares of the stock were exchanged, compared to its average volume of 683,495. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. The stock has a market capitalization of $5.18 billion, a price-to-earnings ratio of -17.74 and a beta of 0.88. The stock's 50-day simple moving average is $115.54 and its 200 day simple moving average is $103.10. Axsome Therapeutics, Inc. has a fifty-two week low of $64.11 and a fifty-two week high of $139.13.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.01. The business had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. On average, equities analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.
Insider Transactions at Axsome Therapeutics
In related news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now owns 42,187 shares in the company, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 22.40% of the company's stock.
Axsome Therapeutics Profile
(
Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Further Reading
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
